# A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

> **NCT04177108** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 242 (actual)

## Conditions studied

- Triple-Negative Breast Cancer

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Ipatasertib
- **DRUG:** Paclitaxel
- **DRUG:** Placebo for Atezolizumab
- **DRUG:** Placebo for Ipatasertib

## Key facts

- **NCT ID:** NCT04177108
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-25
- **Primary completion:** 2023-02-28
- **Final completion:** 2023-02-28
- **Target enrollment:** 242 (ACTUAL)
- **Last updated:** 2024-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04177108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04177108, "A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04177108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*